vs
POPULAR, INC.（BPOP）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
POPULAR, INC.的季度营收约是Revvity的1.1倍（$835.8M vs $772.1M），POPULAR, INC.净利率更高（29.4% vs 12.7%，领先16.7%），过去两年POPULAR, INC.的营收复合增速更高（25.1% vs 9.0%）
Popular Inc.是波多黎各最大的金融服务集团，创立于1893年，总部位于首府圣胡安哈托雷伊商务区的黄金英里金融区。集团提供全方位金融服务，在波多黎各、美属及英属维尔京群岛以Banco Popular品牌运营，美国本土则使用Popular Bank品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BPOP vs RVTY — 直观对比
营收规模更大
BPOP
是对方的1.1倍
$772.1M
净利率更高
BPOP
高出16.7%
12.7%
两年增速更快
BPOP
近两年复合增速
9.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $835.8M | $772.1M |
| 净利润 | $245.7M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 29.4% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | 38.4% | 3.9% |
| 每股收益（稀释后） | $3.78 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BPOPRVTY
| Q1 26 | $835.8M | — | ||
| Q4 25 | $657.6M | $772.1M | ||
| Q3 25 | $646.5M | $698.9M | ||
| Q2 25 | $631.5M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $590.8M | $729.4M | ||
| Q3 24 | $572.5M | $684.0M | ||
| Q2 24 | $568.3M | $691.7M |
净利润BPOPRVTY
| Q1 26 | $245.7M | — | ||
| Q4 25 | $233.9M | $98.4M | ||
| Q3 25 | $211.3M | $46.7M | ||
| Q2 25 | $210.4M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $177.8M | $94.6M | ||
| Q3 24 | $155.3M | $94.4M | ||
| Q2 24 | $177.8M | $55.4M |
毛利率BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 42.4% | 14.5% | ||
| Q3 25 | 38.2% | 11.7% | ||
| Q2 25 | 40.9% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | 37.5% | 16.3% | ||
| Q3 24 | 34.5% | 14.3% | ||
| Q2 24 | 38.4% | 12.4% |
净利率BPOPRVTY
| Q1 26 | 29.4% | — | ||
| Q4 25 | 35.6% | 12.7% | ||
| Q3 25 | 32.7% | 6.7% | ||
| Q2 25 | 33.3% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | 30.1% | 13.0% | ||
| Q3 24 | 27.1% | 13.8% | ||
| Q2 24 | 31.3% | 8.0% |
每股收益（稀释后）BPOPRVTY
| Q1 26 | $3.78 | — | ||
| Q4 25 | $3.51 | $0.86 | ||
| Q3 25 | $3.14 | $0.40 | ||
| Q2 25 | $3.09 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $2.51 | $0.77 | ||
| Q3 24 | $2.16 | $0.77 | ||
| Q2 24 | $2.46 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $17.6M | — |
| 股东权益账面价值 | $6.3B | $7.3B |
| 总资产 | $76.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务BPOPRVTY
| Q1 26 | $17.6M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BPOPRVTY
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.2B | $7.3B | ||
| Q3 25 | $6.1B | $7.4B | ||
| Q2 25 | $6.0B | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $5.6B | $7.7B | ||
| Q3 24 | $5.8B | $7.9B | ||
| Q2 24 | $5.4B | $7.9B |
总资产BPOPRVTY
| Q1 26 | $76.1B | — | ||
| Q4 25 | $75.3B | $12.2B | ||
| Q3 25 | $75.1B | $12.1B | ||
| Q2 25 | $76.1B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $73.0B | $12.4B | ||
| Q3 24 | $71.3B | $12.8B | ||
| Q2 24 | $72.8B | $13.4B |
负债/权益比BPOPRVTY
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | $268.5M | $182.0M | ||
| Q3 25 | $195.0M | $138.5M | ||
| Q2 25 | $242.9M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $199.5M | $174.2M | ||
| Q3 24 | $233.2M | $147.9M | ||
| Q2 24 | $80.4M | $158.6M |
自由现金流BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | $221.1M | $161.8M | ||
| Q3 25 | $141.1M | $120.0M | ||
| Q2 25 | $198.3M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $139.2M | $149.8M | ||
| Q3 24 | $175.6M | $125.6M | ||
| Q2 24 | $38.9M | $136.6M |
自由现金流率BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 33.6% | 21.0% | ||
| Q3 25 | 21.8% | 17.2% | ||
| Q2 25 | 31.4% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | 23.6% | 20.5% | ||
| Q3 24 | 30.7% | 18.4% | ||
| Q2 24 | 6.8% | 19.7% |
资本支出强度BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 7.2% | 2.6% | ||
| Q3 25 | 8.3% | 2.6% | ||
| Q2 25 | 7.1% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 10.2% | 3.4% | ||
| Q3 24 | 10.1% | 3.3% | ||
| Q2 24 | 7.3% | 3.2% |
现金转化率BPOPRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.15× | 1.85× | ||
| Q3 25 | 0.92× | 2.97× | ||
| Q2 25 | 1.15× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.12× | 1.84× | ||
| Q3 24 | 1.50× | 1.57× | ||
| Q2 24 | 0.45× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BPOP
| Net Interest Income | $670.2M | 80% |
| Noninterest Income | $165.6M | 20% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
